Lovastatin Tablet
Product Images NDC 68788-9668

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 68788-9668). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg 100ct

Label for Lovastatin Tablets USP 20 mg, a prescription oral tablet labeled as generic for Mevacor. The label includes directions in English and Spanish, storage instructions, and manufacturer information for Carlsbad Technology, Inc. The tablet is described as round, white, and imprinted with CI 1142. The labeler is Preferred Pharmaceuticals, Inc.*

FDA Label Image

40mg 100ct

Lovastatin Tablets USP 40 mg oral tablet label from Preferred Pharmaceuticals, Inc. The label states each tablet contains 40 mg Lovastatin, USP. It includes storage instructions, manufacturer details as Carlsbad Technology, Inc., and warnings. Directions for use are provided in English and Spanish on a yellow background. Several fillable fields for quantity, lot, batch, expiration, insurance NDC, and product NDC are visible but unfilled.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, depicting its molecular framework including rings, hydroxyl group, and functional groups characteristic of the active ingredient in Lovastatin tablets.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing various drugs or grapefruit juice co-administered with Lovastatin. It lists the number of subjects, dosing details of the coadministered drug or grapefruit juice, Lovastatin dosing, and the area under the curve (AUC) ratio with or without the coadministered drug, comparing Lovastatin and Lovastatin acid exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph depicting acute major coronary events as the primary endpoint, showing the proportion of participants without event over six years of follow-up. Two groups are compared: Lovastatin and Placebo, with Lovastatin demonstrating a 37% risk reduction (p < 0.001) relative to Placebo.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' for Lovastatin tablets. It lists interacting agents including strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, alongside prescribing recommendations such as contraindications, dose limitations, and avoidance instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.